Oryzon's Iadademstat Shows Strong Efficacy in AML Trials, Accelerates Development Plans
Event summary
- Oryzon to present updated Phase Ib trial data for iadademstat in AML at EHA 2026, showing 100% ORR and 93% CRc in first-line setting with azacitidine and venetoclax.
- In FLT3-mutated relapsed/refractory AML, iadademstat with gilteritinib achieved 67% CRc with favorable safety profile.
- Company plans accelerated clinical development for iadademstat in first-line AML based on emerging data.
- Presentations scheduled for June 12-13, 2026 in Stockholm, Sweden.
The big picture
Oryzon's positive Phase Ib data for iadademstat in AML comes as the field sees increasing focus on combination therapies targeting specific genetic mutations. The strong response rates in both first-line and relapsed/refractory settings position the drug as a potential differentiator in a competitive oncology market. The company's accelerated development plans reflect growing confidence in the asset's commercial potential, particularly as precision medicine approaches gain traction in hematologic malignancies.
What we're watching
- Clinical Validation
- Whether the mature data from ALICE-2 trial will confirm the strong preliminary efficacy signals and support regulatory approval pathways.
- Development Strategy
- The pace at which Oryzon can advance iadademstat through accelerated clinical development in first-line AML.
- Competitive Positioning
- How these results position iadademstat against emerging therapies in AML, particularly in combination regimens.
Related topics